Remarkable advancements have been made in the treatment outcomes of multiple myeloma (MM) patients; however, for frail elderly patients, these treatment outcomes are still insufficient. Elderly MM patients are increasing, as are their treatment regimens. There is a heightened demand to assess these patients in order to provide optimized treatments. While continuous treatment is more common for MM patients when compared to fixed-duration treatment, due to the risk of treatment interruption causing reduced survival rates, effectiveness and safety are essential. Treatment goals vary for each patient, but must preserve their quality of life (QOL). When planning treatments for these patients, frailty evaluation is increasingly emphasized as a stratification factor which helps develop accurate screening tools. Daratumumab (DARA) therapy, used globally, is not only effective in frail elderly MM patients, but also has QOL benefits. Proficiency in utilizing DARA regimens is potentially advantageous for patients not included in clinical trials, and innovative usage can further broaden its scope. The development of tools to accurately assess frailty and the establishment of optimal treatments for frail elderly MM patients are imperative. This review is an overview, challenging the frailty assessments for MM patients, re-examining the evidence for DARA regimens in frail elderly MM patients, and discussing potential areas for improvement.
Purpose To evaluate the effectiveness, treatment durability, and infectious complications of frontline daratumumab, lenalidomide, and dexamethasone (DRd) in patients aged > 80 years with transplant-ineligible newly diagnosed multiple myeloma (Ti-NDMM) and to explore associations between baseline nutritional vulnerability and treatment outcomes. Methods We retrospectively analyzed consecutive patients aged > 80 years with Ti-NDMM who received frontline DRd. Treatment outcomes and infectious complications were also evaluated. Exploratory analyses were performed according to baseline nutritional indices, including the Prognostic Nutritional Index (PNI) and Geriatric Nutritional Risk Index. Results Fifteen patients were included. The overall response rate was 93.3%, and 53.3% of patients achieved a very good partial response or better. After a median follow-up of 23.1 months, the estimated median duration of treatment (DOT), time to the next treatment, and progression-free survival (PFS) were 36.7, 44.6, and 40.0 months, respectively, while the estimated median overall survival was not reached. Infectious complications, including two infection-related deaths, represented a major barrier to treatment continuation. Severe infections predominantly occurred within the first year of treatment initiation. In exploratory analyses, patients with a low baseline PNI had a shorter DOT (30.8 months vs. not reached; p = 0.049) and more frequent grade 3–5 infections (71.4% vs. 12.5%; p = 0.041). Conclusion Frontline DRd demonstrated favorable effectiveness and clinically meaningful treatment durability in patients aged > 80 years with Ti-NDMM. Infectious complications, particularly during the early treatment period, frequently compromised the continuation of treatment. Exploratory analyses suggested that a lower baseline PNI may be associated with severe infectious complications and a shorter treatment durability.